These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 17671215)

  • 1. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
    Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
    Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
    Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
    Wilhelm M; Kunzmann V; Eckstein S; Reimer P; Weissinger F; Ruediger T; Tony HP
    Blood; 2003 Jul; 102(1):200-6. PubMed ID: 12623838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronate stimulates gamma delta T cells in prostate cancer patients.
    Naoe M; Ogawa Y; Takeshita K; Morita J; Shichijo T; Fuji K; Fukagai T; Iwamoto S; Terao S
    Oncol Res; 2010; 18(10):493-501. PubMed ID: 20681408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.
    Nussbaumer O; Gruenbacher G; Gander H; Thurnher M
    Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
    Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M
    Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
    Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
    J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
    Kobayashi H; Tanaka Y; Shimmura H; Minato N; Tanabe K
    Anticancer Res; 2010 Feb; 30(2):575-9. PubMed ID: 20332473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
    Poonia B; Pauza CD
    Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
    Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
    J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
    Li Z; Tang J; Sun L; Ye Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
    Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
    J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
    Pressey JG; Adams J; Harkins L; Kelly D; You Z; Lamb LS
    Medicine (Baltimore); 2016 Sep; 95(39):e4909. PubMed ID: 27684826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
    Wada I; Matsushita H; Noji S; Mori K; Yamashita H; Nomura S; Shimizu N; Seto Y; Kakimi K
    Cancer Med; 2014 Apr; 3(2):362-75. PubMed ID: 24515916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
    Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
    J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.